136507-15-8

Basic information

• Product Name: 2-METHOXY-4-NITROBENZALDEHYDE
• Synonyms: 2-METHOXY-4-NITROBENZALDEHYDE;2-FORMYL-5-NITROANISOLE;4-Nitro-2-Methoxybenzaldehyde;2-Methoxy-4-nitrobenzaldehyde 97%;Benzaldehyde, 2-methoxy-4-nitro-
• CAS NO: 136507-15-8
• Molecular Formula: C₈H₇NO₄
• Molecular Weight: 181.15
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Aldehydes;C8;Carbonyl Compounds
• Mol File: 136507-15-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 120-124 °C
• Boiling Point: 354.728 °C at 760 mmHg
• Flash Point: 184.222 °C
• Appearance: /
• Density: 1.323 g/cm³
• Vapor Pressure: 3.28E-05mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-METHOXY-4-NITROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-4-NITROBENZALDEHYDE(136507-15-8)
• EPA Substance Registry System: 2-METHOXY-4-NITROBENZALDEHYDE(136507-15-8)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 136507-15-8(Hazardous Substances Data)

Usage

Uses

2-Methoxy-4-nitrobenzaldehyde is used in perparation of N-((oxazolyl)phenyl)chromanecarboxamide derivatives as therapeutically active substances for the treatment of retinal diseases.

InChI:InChI=1/C8H7NO4/c1-13-8-4-7(9(11)12)3-2-6(8)5-10/h2-5H,1H3

Upstream product

• 13120-77-9 2-methyl-5-nitroanisole 
• 16855-08-6 2-hydroxy-6-nitrobenzaldehyde 
• 74-88-4 methyl iodide 
• 97-52-9 2-methoxy-4-nitrophenylamine 
• 201230-82-2 carbon monoxide 
• 39106-79-1 methyl 2-methoxy-4-nitrobenzoate 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 858213-45-3 α'-acetoxy-2,2'-dimethoxy-4,4'-dinitro-bibenzyl-α-ol 
• 101118-65-4 α,α'-dibromo-2,2'-dimethoxy-4,4'-dinitro-bibenzyl 
• 5428-54-6 2-methyl-5-nitrophenol 
• 136507-13-6 acetic acid 2-methoxy-4-nitro-benzyl ester 
• 90434-16-5 1-(bromomethyl)-2-methoxy-4-nitrobenzene 
• 136507-14-7 (2-methoxy-4-nitrophenyl)methanol 
• 112689-80-2 α,α'-diacetoxy-2,2'-dimethoxy-4,4'-dinitro-bibenzyl 

Downstream Products

• 497854-58-7 (2-methoxy-4-nitrophenyl)(pyridin-2-yl)methanol 
• 876143-71-4 2-(2-Methoxy-4-nitrophenyl)-1,3-dioxolane 
• 2460-58-4 2-hydroxy-4-nitrobenzaldehyde 
• 136507-16-9 C₈H₇⁽¹⁸⁾FO₂ 
• 2597-56-0 4-nitro-o-anisic acid 

Relevant articles and documents

Novel amide-based inhibitors of inosine 5′-monophosphate dehydrogenase

A series of novel amide-based small molecule inhibitors of inosine monophosphate dehydrogenase (IMPDH) was explored. The synthesis and the structure-activity relationships (SARs) derived from in vitro studies are described.

Substitution Effect on 2-(Oxazolinyl)-phenols and 1,2,5-Chalcogenadiazole -Annulated Derivatives: Emission-Color-Tunable, Minimalistic Excited-State Intramolecular Proton Transfer (ESIPT)-Based Luminophores

Minimalistic 2-(oxazolinyl)-phenols substituted with different electron-donating and -withdrawing groups as well as 1,2,5-chalcogenadiazole-annulated derivatives thereof were synthesized and investigated in regard to their emission behavior in solution as well as in the solid state. Depending on the nature of the incorporated substituent and its position, emission efficiencies were increased or diminished, resulting in AIE or ACQ characteristics. Single-crystal analysis revealed J- and H-type packing motifs and a so-far undescribed isolation of ESIPT-based fluorophores in the keto form.

Synthesis of green emitting coumarin bioconjugate for the selective determination of flu antigen

-

Orally active CCR5 antagonists as anti-HIV-1 agents 2: Synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety

In order to develop orally active CCR5 antagonists, we investigated 1-benzoxepine derivatives containing new polar substituents, such as phosphonate, phosphine oxide or pyridine N-oxide moieties, as replacements for the previoiusly reported quaternary ammonium moiety. Among these compounds, the 2-(α-hydroxybenzyl)pyridine N-oxide 5e exhibited moderate CCR5 antagonistic activity and had an acceptable pharmacokinetic profile in rats. Subsequent chemical modification was performed and compound (S)-5f possessing the (S)-configuration hydroxy group was found to be more active than the (R)-isomer. Replacement of the 1-benzoxepine ring with a 4-methylphenyl group by a 1-benzazepine ring with a 4-[2-(butoxy)ethoxy]phenyl group enhanced the activity in the binding assay. In addition, introduction of a 3-trifluoromethyl group on the phenyl group of the anilide moiety led to greatly increased activity in the HIV-1 envelope-mediated membrane fusion assay. In particular, compound (S)-5s showed the most potent CCR5 antagonistic activity (IC 50=7.2 nM) and inhibitory effect (IC50=5.4 nM) in the fusion assay, together with good pharmacokinetic properties in rats.